Non-Invasive Biomarkers in Cystic Fibrosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00413140|
Recruitment Status : Completed
First Posted : December 19, 2006
Last Update Posted : December 19, 2006
Background Chronic airway inflammation is present in cystic fibrosis. Non-invasive inflammometry may be useful in disease management.
Objective We studied 1) the ability of fractional exhaled nitric oxide and inflammatory markers (acidity, nitrite, nitrate, hydrogen peroxide, 8-isoprostane, interferon-γ, tumor necrosis factor-α, interleukin-2,-4,-5,-10) in exhaled breath condensate, to discriminate between cystic fibrosis and control children, and, 2) the relationship of biomarkers with control and severity of cystic fibrosis.
Methods In 98 children (48 cystic fibrosis / 50 controls), condensate was collected using a glass condenser. Exhaled nitric oxide was measured using the NIOX®.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Biomarkers in Exhaled Breath Indicate Presence, Control and Severity of Cystic Fibrosis|
|Study Start Date :||June 2004|
|Estimated Study Completion Date :||May 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00413140
|University Hospital Maastricht|
|Maastricht, Netherlands, 6202AZ|
|St Radboud Childrens Hospital|
|Máxima Medical Centre|
|Principal Investigator:||Charlotte M Robroeks, M||Maastricht University Medical Center|
|Study Director:||Edward Dompeling, MD, PhD||Maastricht University Medical Center|
|Study Director:||Quirijn Jöbsis, MD, PhD||Maastricht University Medical Center|